Quadrant Capital Group LLC Boosts Stock Position in Eli Lilly and Company (NYSE:LLY)

Quadrant Capital Group LLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 1.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,625 shares of the company’s stock after buying an additional 110 shares during the period. Eli Lilly and Company comprises about 0.5% of Quadrant Capital Group LLC’s investment portfolio, making the stock its 27th largest position. Quadrant Capital Group LLC’s holdings in Eli Lilly and Company were worth $6,193,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Tranquility Partners LLC raised its stake in Eli Lilly and Company by 14.5% during the third quarter. Tranquility Partners LLC now owns 814 shares of the company’s stock valued at $437,000 after buying an additional 103 shares in the last quarter. Byrne Asset Management LLC raised its holdings in shares of Eli Lilly and Company by 55.0% during the third quarter. Byrne Asset Management LLC now owns 541 shares of the company’s stock worth $291,000 after purchasing an additional 192 shares during the period. Manhattan West Asset Management LLC bought a new position in shares of Eli Lilly and Company in the 3rd quarter worth about $338,000. Allworth Financial LP boosted its holdings in shares of Eli Lilly and Company by 14.6% in the 3rd quarter. Allworth Financial LP now owns 5,288 shares of the company’s stock valued at $2,840,000 after buying an additional 672 shares during the period. Finally, Optas LLC raised its stake in Eli Lilly and Company by 66.1% during the third quarter. Optas LLC now owns 2,074 shares of the company’s stock worth $1,114,000 after acquiring an additional 825 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 0.2 %

Shares of LLY traded down $1.37 during mid-day trading on Friday, reaching $769.75. The company’s stock had a trading volume of 859,868 shares, compared to its average volume of 3,004,482. The company has a market cap of $731.58 billion, a price-to-earnings ratio of 113.64, a price-to-earnings-growth ratio of 1.56 and a beta of 0.37. The business has a fifty day moving average of $760.50 and a 200 day moving average of $682.89. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a 1 year low of $419.80 and a 1 year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same quarter in the prior year, the business earned $1.62 EPS. The company’s revenue for the quarter was up 26.0% compared to the same quarter last year. As a group, analysts forecast that Eli Lilly and Company will post 13.82 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Shareholders of record on Thursday, May 16th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.68%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on LLY. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 1st. Bank of America lifted their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Citigroup increased their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Finally, Wells Fargo & Company boosted their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $769.53.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.